At this year’s World CB & CDx conference held in Boston, Dylan Marchione, PhD, of Servier Pharmaceuticals presented data supporting the use of the Tapestri Platform in clinical development to elucidate clonal evolution patterns in patients with IDH1-mutated AML treated with combination therapy, TIBSOVO + azacitidine, as compared to monotherapy.
